The ENCORE study evaluated Arikayce in combination with standard multidrug therapy and met both primary and secondary endpoints, demonstrating improved respiratory symptom scores and higher rates of culture conversion. Adverse events were consistent with known side effects, while discontinuation rates declined due to greater patient and physician familiarity.

Positive data support expanding Arikayce use beyond refractory patients, increasing the target population from about 30,000 to roughly 200,000 patients across the U.S. and Japan. This broader indication could substantially boost long-term growth prospects for the drug.

Insmed plans to file for Arikayce label expansion in the second half of 2026, with analysts projecting revenue impact beginning in 2027. Near-term investor attention is expected to remain on the upcoming launch of its other therapy, Brinsupri, which is forecast to drive momentum into year-end.